PMID: 12195242
Systematic capture of dosing patterns, formulation source, route of administration, and standardized clinical outcomes may be more informative than continued reliance on heterogeneous mechanistic studies
When it was recognized that pellagra, a condition marked by diarrhea, dermatitis, dementia, and mortality, could be treated with foods containing NAD+ precursors, particularly vitamin B3, the clinical significance of maintaining NAD+ levels was established in the early 1900s (9). Notably, the skin does not flush with NAD+ injection, in contrast to vitamin B3 (niacin) intake, which also causes this negative effect (10). Low NAD+ levels have recently been associated with a variety of age-related ailments and diseases linked to increased oxidative/free radical damage, including diabetes, heart disease, vascular dysfunction, ischemic brain injury, Alzheimers disease, and vision loss (8, 11-17)
Understanding dementia risk: modifiable vs
The substantial weight reduction observed with tirzepatide monotherapy (15-21% body weight in clinical trials) suggests that any perceived benefits likely reflect tirzepatide's pharmacological effects rather than synergistic action
Frequency depends on your levels and goals
